Key result
Switching from carvedilol to olmesartan narrows pulse pressure by ~35 mmHg in a case report.
Why the study?
Widened pulse pressure reflects reduced large-artery compliance with a broad differential diagnosis, and antihypertensive drug classes differentially affect its reduction, with RAAS inhibitors and calcium channel blockers showing greater benefit.
Does substituting beta-blockade (carvedilol) with RAAS inhibition (olmesartan/losartan) alongside insulin resumption narrow wide pulse pressure and improve hemodynamic control in an elderly patient with hypertension and insulin-dependent diabetes?
Case Report (n=1)
No
Does substituting beta-blockade (carvedilol) with RAAS inhibition (olmesartan/losartan) alongside insulin resumption narrow wide pulse pressure and improve hemodynamic control in an elderly patient with hypertension and insulin-dependent diabetes?
This case illustrates the hemodynamic benefit of favoring RAAS inhibitors over beta-blockers to reduce wide pulse pressure without causing excessive diastolic hypotension in elderly patients with diabetes and arterial stiffness, while highlighting the critical role of continuous medication access.
Single-case observation of pulse pressure narrowing; leaves open whether olmesartan substitution warrants trials in older adults with diabetes.
Widened pulse pressure (PP) is a marker of reduced large-artery compliance, most often attributed to age- and diabetes-related arteriosclerosis, but its differential includes aortic regurgitation, hyperthyroidism, arteriovenous fistula, and severe anemia. Antihypertensive drug classes may differentially affect PP, with renin-angiotensin-aldosterone system (RAAS) inhibitors and calcium channel blockers showing greater benefit on its reduction. A 67-year-old woman with hypertension and insulin-dependent diabetes presented with polyuria, dizziness, wide PP (70 mmHg), tachycardia, hyperglycemia, and peripheral edema after prolonged discontinuation of losartan and insulin due to public pharmacy shortages. Aortic regurgitation was excluded by absence of a diastolic murmur and by echocardiography, which showed aortic arch atheromatosis and mild valve calcification without regurgitation. Substitution of carvedilol with olmesartan, alongside correction of hyperglycemia-driven dehydration, was associated with progressive narrowing of PP. This case highlights the clinical rationale for favoring RAAS inhibition over beta-blockade, while emphasizing that medication affordability and supply continuity are as clinically fundamental as pharmacologic choice in resource-limited settings.
No takes yet. Share an insight, caveat, or question.
Monteiro et al. (2026) conducted a case report in Wide pulse pressure, hypertension, and insulin-dependent diabetes mellitus (n=1). Olmesartan (switched from carvedilol) followed by resumption of losartan and insulin glargine vs. Carvedilol 6.125 mg twice daily (prior therapy) was evaluated on Pulse pressure (mmHg). Switching from carvedilol to olmesartan 40 mg daily narrowed pulse pressure from 80-90 mmHg down to 50 mmHg (BP 140/90 mmHg) within 1 week in a 67-year-old woman with diabetes and hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: